Number of participants with major bleeding within 7 days of surgery (bleeding that required ≥ 2 units of whole blood/red blood cells within 24 hours of the bleeding) · people with a low platelet count
1 finding from 1 review
Intervention not reported
Red blood cell transfusion requirements (units of red blood cells per patient per month) · patients with myelodysplastic syndrome
1 finding from 1 review
Death during study period · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
MSCs showed no clear difference in all‐cause mortality (prophylactic trials) (over duration of trial) compared with control/placebo (low certainty).
2 findings from 1 review
Safety of MSC infusion · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
1 finding from 1 review
Health‐related quality of life · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse of malignant disease (prophylactic trials) (>12‐month · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
MSCs showed no clear difference in relapse of malignant disease (prophylactic trials) (>12‐month compared with control/placebo (low certainty).
1 finding from 1 review
Incidence of acute GvHD (prophylactic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
MSCs showed no clear difference in incidence of acute GvHD (prophylactic trials) compared with control/placebo (low certainty).
1 finding from 1 review
Incidence of chronic GvHD (prophylactic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
MSCs may leads to lower incidence of chronic GvHD (prophylactic trials) compared with control/placebo (low certainty).
1 finding from 1 review
Acute GvHD complete response (therapeutic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
It is very uncertain whether MSCs changes acute GvHD complete response (therapeutic trials) compared with control/placebo (very low certainty).
1 finding from 1 review
Chronic GvHD complete response (therapeutic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
It is very uncertain whether MSCs changes chronic GvHD complete response (therapeutic trials) compared with control/placebo (very low certainty).
1 finding from 1 review